Inclusion Criteria:

- Age 18 or older.

- Patient with at least 5 actinic keratoses of the face at Day 0.

- Patient was willing to use an adequate contraceptive method or was surgically
sterile, post menopausal, abstinent or with a same sex partner. Adequate means of
contraception included oral contraceptives, IUD in use for 30 days before Day 0,
barrier methods and spermicide in use at least 14 days before Day 0.

- Patient capable of giving informed consent.

Exclusion Criteria:

- Patient with allergy to methylaminolevulinate or any component of the vehicle which
includes peanut and almond oil.

- Patient with clinically significant sensitivity to visible light, porphyria or
porphyrin sensitivity.

- Patient used any topical treatment for actinic keratoses (including imiquimod and
5-fluouracil), on the face within 4 weeks preceding Day 0.

- Patient had cryotherapy or surgery on the face within 4 weeks preceding Day 0.

- Patient with any malignant skin lesion (such as basal cell carcinoma, invasive
squamous cell carcinoma or Bowen's disease) on the face at Day 0.

- Patient used photodynamic therapy, with any topical or systemic photosensitizer
within 8 weeks preceding Day 0.

- Patient was exposed to excessive ultraviolet radiation (UVB phototherapy, sun tanning
salons) within the 4 weeks preceding Day 0.

- Patient used any investigational drug within 4 weeks preceding Day 0.

- Patient with problems of alcoholism or drug abuse in the past year.

- Patient with any unstable or serious uncontrolled medical condition.

- Current pregnancy or lactation.

- Patient with any serious dermatological disorder, including malignancies that would
either put the patient at risk or interfere with efficacy or safety evaluations.

- Patient with Fitzpatrick phototype IV, V or VI (inadequate penetration of red light
in dark skinned subjects.

- Patients with extensive facial hair (e.g., beard) that would either impair red light
exposure or interfere with lesion evaluation.